comparemela.com

Page 8 - Lawrence Blatt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aligos Therapeutics (ALGS) Presents Clinical Data from NASH Program

Aligos Therapeutics (ALGS) Presents Clinical Data from NASH Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalMattheww mcclureAmy jobeCorey davisLawrence blattAligos therapeutics incExchange commissionExchange commission onLifesci communicationsWall streetParis hepatology conferenceScientific presentationsFavorable safetyPharmacokinetic profileDose proportionally lowers lipid biomarkersChief medical officer

Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference

Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Contactcorey davisLawrencem blattContactamy jobeLawrence blattPh dlifesci communicationsAligos therapeutics incExchange commissionExchange commission onGlobal biopharma conferenceVirtual healthcare conference informationSecurities litigation reform actAligo quarterly report

Aligos Trims Staff to Hone Focus on Early Clinical Programs in NASH, Covid-19

The Aligos Therapeutics pipeline reprioritization comes after clinical trial setbacks to two hepatitis B drug candidates led the biotech to end both programs. Still intact is a Merck research collaboration focused on developing NASH therapies.

Pardes biosciencesLawrence blattMadrigal pharmaceuticalsSouth san francisco based aligosWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan franciscoLife sciencesRock healthStartup adviceStartup fundingPatient monitoring systemOtion sensors

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

08.02.2023 - – Pipeline reprioritization emphasizes NASH and COVID-19 assets, ALG-055009 and ALG-097558, plus key ongoing collaborations, including the Merck & Co. (MSD) programs in NASH –– Overall workforce reduction (attrition and reduction in force) of . Seite 1

Lawrence blatt

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD s The Liver Meeting 2022 Seite 1

04.11.2022 - ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos’ oral and poster . Seite 1

Lawrence blattAligos therapeutics incLiver meetingAmerican associationLiver diseasesScientific presentations

vimarsana © 2020. All Rights Reserved.